BillionToOne Q3 Revenue $83.52M Beats Consensus
Reports Q3 revenue $83.52M, consensus $82.9M. "This quarter reinforced our view about how a unique, innovative technology combined with disciplined execution can drive a differentiated financial profile in molecular diagnostics," said Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne. "The incredible strength and momentum across our prenatal and oncology businesses reflects a deliberate commitment to scientific rigor paired with resourceful, step-by-step execution. We continue to earn the trust of providers, patients, payors, and health systems, and rapidly grow our test volumes by solving unmet clinical needs. As we begin our path as a public company, we remain guided by the same principles we started with-relentless focus and an unwavering commitment to re-defining molecular diagnostics."
